Core Insights - Dong-E E-Jiao Co., Ltd. has been designated as a strategic partner by the Shandong Sports Bureau, providing comprehensive support to the Shandong delegation during the 15th National Games [1][2] - The company’s three core products—Dong-E E-Jiao, Compound E-Jiao Syrup, and Peach Blossom E-Jiao Cake—were awarded the title of "Designated Products for the Shandong Sports Delegation" [1][2] - Dong-E E-Jiao emphasizes its commitment to supporting local sports development as part of its corporate social responsibility, aligning its growth with regional sports initiatives [1] Company Initiatives - During the current National Games cycle, Dong-E E-Jiao has focused on enhancing its research system, product quality management, and supply chain capabilities to support sports initiatives [2] - The inclusion of its three core products in the designated product matrix reflects the company's comprehensive strength in quality systems, standard management, and supply chain capabilities [2] - Dong-E E-Jiao aims to continue integrating traditional Chinese medicine with modern sports health, driving innovation and expanding its collaboration with the sports health system [2]

Group 1 - The core viewpoint of the news highlights a significant increase in the sales of cold and flu medications due to a rapid rise in flu activity across the country since November, with specific products like Oseltamivir and Mabalosavir seeing sales surges of 237% and 180% respectively [1] - The China Securities Index for Traditional Chinese Medicine (930641) has shown a positive performance, with a 0.87% increase, and notable gains in constituent stocks such as Guangdong Wannianqing (20.02%) and Zhongheng Group (9.70%) [1] - The early onset of the flu season this year is expected to lead to a peak in positive infection rates for flu-related emergency visits, surpassing last year's levels, indicating a potential increase in demand for respiratory infection-related products [1] Group 2 - As of October 31, 2025, the top ten weighted stocks in the China Securities Index for Traditional Chinese Medicine account for 54.92% of the index, with major companies including Yunnan Baiyao, Pian Zai Huang, and Tong Ren Tang [2] - The Traditional Chinese Medicine ETF (159647) closely tracks the performance of the China Securities Index for Traditional Chinese Medicine, which includes publicly listed companies involved in the production and sale of traditional Chinese medicine [1][3]

Core Viewpoint - New Tian Pharmaceutical's stock rose by 2.27% to a closing price of 10.80 yuan, with significant block trades occurring on November 25 [1] Trading Activity - A total of three block trades were executed, with a combined trading volume of 633,000 shares and a total transaction value of 6.0135 million yuan [1] - The first trade had a price of 9.50 yuan for 211,000 shares, amounting to 2.0045 million yuan, with a discount rate of -12.04% [1] - The second trade mirrored the first, also at 9.50 yuan for 211,000 shares and a transaction value of 2.0045 million yuan, with the same discount rate [1] - The third trade was identical in price and volume, executed at 9.50 yuan for 211,000 shares, totaling 2.0045 million yuan, with the buyer being a different brokerage [1] Recent Performance - Over the past three months, the stock has seen a total of three block trades with a cumulative transaction value of 6.0135 million yuan [1] - In the last five trading days, the stock has declined by 3.91%, with a net outflow of 4.9137 million yuan in principal funds [1]

Core Insights - The article highlights the successful global registration and commercialization of 17 innovative traditional Chinese medicine (TCM) products by Yiling Pharmaceutical, marking a significant step in the internationalization of TCM [1][5][6] - Yiling Pharmaceutical has established a clear pathway for TCM's global integration, moving from physical expansion to cultural integration and value leadership [1][5] Group 1: Global Expansion of TCM - Yiling Pharmaceutical has successfully registered its innovative TCM products in over 50 countries and regions, demonstrating the global reach of Chinese medicine [1][5] - The company emphasizes the importance of theoretical foundations in TCM's internationalization, having developed a comprehensive theory system around "Luo disease" over 33 years [5][6] - The establishment of various international academic exchange platforms has facilitated the global dissemination and research of Luo disease theory [6][9] Group 2: Cultural Integration and Market Strategies - Yiling Pharmaceutical adopts a differentiated market strategy, tailoring its approach to meet the specific medical needs and cultural contexts of different regions [7][8] - In developed countries, the focus is on high-level clinical research to gain trust from the academic and regulatory communities, while in emerging markets, the company integrates its products into local healthcare systems [7][8] - The successful inclusion of Tongxinluo capsules in Vietnam's healthcare system exemplifies the company's effective local integration strategy [7] Group 3: Evidence-Based Medicine and Research - Yiling Pharmaceutical leads in evidence-based research, establishing a robust research framework that supports the clinical efficacy of its TCM products [9][10] - The company has conducted over 40 high-quality evidence-based studies on its innovative TCM products, with significant findings published in prestigious international medical journals [10][12] - This research not only validates the safety and efficacy of TCM but also presents its benefits in modern scientific language, enhancing its global acceptance [10][12] Group 4: Future Outlook and Challenges - Despite the progress, Yiling Pharmaceutical acknowledges ongoing challenges in cultural recognition and regulatory policies, particularly in non-Belt and Road countries [12] - The company believes that collaboration among government, industry, academia, and research institutions is essential to overcome these barriers and further the global impact of TCM [12]

Core Insights - On November 24, brokerages set target prices for listed companies, with notable increases for Fangsheng Pharmaceutical, Juhua Co., and Meihua Biological, showing target price increases of 46.38%, 38.81%, and 32.68% respectively, all belonging to the traditional Chinese medicine and chemical products industries [1][2]. Group 1: Target Price Increases - Fangsheng Pharmaceutical received a target price of 16.60 yuan, reflecting a target price increase of 46.38% [2]. - Juhua Co. was assigned a target price of 46.00 yuan, indicating a target price increase of 38.81% [2]. - Meihua Biological's target price was set at 13.44 yuan, with a target price increase of 32.68% [2]. - Other companies with significant target price increases include Toukeng Life (28.14% increase) and Yiling Pharmaceutical (18.30% increase) [2]. Group 2: Brokerage Recommendations - On November 24, a total of 23 listed companies received brokerage recommendations, with companies like Keshun Co., Jinhong Group, and Meihua Biological receiving one recommendation each [2]. - Fangsheng Pharmaceutical was covered for the first time by Guotai Junan Securities with an "Increase" rating [3]. - Other companies receiving first-time coverage include Linuo Pharmaceutical (Increase rating), Yinglian Co. (Increase rating), Huaxia Eye Hospital (Recommendation rating), and Yike Medical (Outperform rating) [3].

Group 1 - The core viewpoint of the news highlights the strong performance of the Traditional Chinese Medicine (TCM) sector, driven by supportive government policies aimed at innovation and industrial transformation [1][2] - The Shanghai government has issued a document encouraging collaboration among medical institutions, research units, and pharmaceutical companies to create platforms for TCM innovation and industrial transformation [1] - The document supports the development of major TCM varieties and the secondary development of classic varieties, as well as the establishment of mechanisms for collecting and organizing human experience data for drug registration [1] Group 2 - China Galaxy Securities anticipates that policy-driven changes will continue to propel the pharmaceutical industry towards innovation and upgrades, with a focus on finding incremental opportunities in niche markets [2] - The report indicates that domestic innovative drugs are expected to yield results, with several second-generation I/O drugs and ADCs entering phase three clinical trials, which is promising for future developments [2] - The TCM prescription drug market is facing clinical re-evaluation, which may reshape the market landscape and potentially lead to a turning point in TCM gross margins [2] Group 3 - The TCM ETF closely tracks the Zhongzheng TCM Index, which selects listed companies involved in TCM production and sales to reflect the overall performance of TCM concept stocks [2] - As of October 31, 2025, the top ten weighted stocks in the Zhongzheng TCM Index account for 54.92% of the index, including companies like Yunnan Baiyao and Tongrentang [2]

Core Insights - On November 24, 2023, brokerage firms set target prices for listed companies, with notable increases for Fangsheng Pharmaceutical, Juhua Co., and Meihua Biological, showing target price increases of 46.38%, 38.81%, and 32.68% respectively [1] Company Summaries - Fangsheng Pharmaceutical is in the traditional Chinese medicine sector and has the highest target price increase among the listed companies [1] - Juhua Co. operates in the chemical products industry and ranks second in target price increase [1] - Meihua Biological, also in the chemical products sector, ranks third with a significant target price increase [1] Brokerage Recommendations - A total of 23 listed companies received brokerage recommendations on November 24, 2023 [1] - Companies such as Keshun Co., Jinhong Group, and Meihua Biological received recommendations from one brokerage firm each [1]

万联证券认为，2025年以来，中药板块在药店和院内渠道销售疲软影响下业绩承压，上市公司业绩分 化，整体看，OTC领域龙头企业业绩韧性较强，在医保改革背景下，中药行业正经历发展模式转型的阵 痛期，未来多元化渠道、高品牌力和高临床价值是关键。长期看，政策引导行业走向高质量和规范化发 展。 华金证券认为，把握中药板块精品+创新两大主线。1）精品中药兼具医疗价值与消费属性，品牌效应 明显，对应高净值客户，议价能力较强；2）创新中药在利好政策的支持与外部环境正向刺激下正在逐 渐迎来收获期，中药改良型新药、古代经典名方等中药创新药有望持续以临床为导向加速研制，并实现 商业化放量，政策催生的结构性机遇凸显。 （原标题：机构：把握中药板块精品+创新两大主线） 上海市人民政府办公厅印发《上海市全面深化药品医疗器械监管改革促进医药产业高质量发展的若干措 施》，其中提出，支持中药研发创新。制订医疗机构应用传统工艺配制中药制剂备案管理规定。支持疗 效确切、特色优势明显的医疗机构中药制剂及名老中医方开发转化为中药新药。鼓励医疗机构、研发单 位和药品企业共同打造中药创新与产业转化平台，支持中药创新药临床研究和古代经典名方中药复方制 剂研 ...

Core Viewpoint - Hansen Pharmaceutical (002412.SZ) is currently in the process of scaling up the research for its new traditional Chinese medicine product, Cangrong Granules, which is in the stage of pilot testing [1] Group 1 - The company is focusing on research and development in the field of traditional Chinese medicine [1] - Cangrong Granules is a new drug under development by the company [1] - The current phase of research involves pilot testing for process scaling [1]

Core Insights - The fifth Huaxia Health Industry Development and Rehabilitation Service Conference was held in Beijing, where Yiling Pharmaceutical was recognized for its achievements in traditional Chinese medicine innovation, being selected as a "2025 Annual Traditional Chinese Medicine Innovation Model Case" [1] Group 1: R&D Investment and Achievements - Yiling Pharmaceutical prioritizes R&D as the core driver of its development, with R&D investment reaching 544 million yuan in the first three quarters of 2025, accounting for 9.27% of its operating revenue, leading the industry [3] - Cumulatively, from 2019 to 2024, the company has invested over 5 billion yuan in R&D, establishing a virtuous cycle of "investment-transformation-reinvestment" to produce "Chinese medicine" that aligns with the genetic and physical characteristics of the Chinese population [3] - In 2025, Yiling Pharmaceutical's R&D pipeline has yielded significant results, including the approval of the traditional Chinese medicine Qifang Nasal Congestion Tablets by the National Medical Products Administration, which has also been registered in Macau, marking it as the first registered innovative traditional Chinese medicine in Macau [3] Group 2: Product Development and Market Impact - Four new traditional Chinese medicines, including Qigui Luobitong Tablets and Children's Lianhua Qingwen Granules, are in the application stage, while five others are undergoing clinical research, covering major diseases in respiratory, rheumatology, and neurology fields [3] - Yiling Pharmaceutical holds 17 patented traditional Chinese medicines that address major diseases such as cardiovascular, respiratory, and endocrine disorders, with 11 products included in the national medical insurance catalog and five in the national essential drug catalog, effectively reducing the medication burden on patients [3] Group 3: Evidence-Based Medicine and Global Outreach - The company emphasizes high-standard evidence-based medical research to promote traditional Chinese medicine globally, with its series of studies on vascular event chain interventions attracting international attention, published in top medical journals such as JAMA and Nature Medicine [4] - Yiling Pharmaceutical has initiated over 40 evidence-based medical studies, establishing a research evidence system that integrates traditional Chinese and Western medicine [4] Group 4: Industry Recognition and Innovation - The selection process for the innovation model cases involved extensive research and professional evaluation by hundreds of media outlets, experts, and industry scholars, highlighting representative and exemplary innovation cases across various dimensions, including corporate practices, technology applications, brand building, and cultural stories [4][5] - The release and display of these cases aim to convey a positive industry trend, promote a pragmatic and innovative spirit, and foster the healthy development of enterprises in the health sector [5]